Cause and susceptible dogs
Merck describes canine parvovirus (CPV) as a nonenveloped, single-stranded DNA virus thought to have arisen from feline panleukopenia virus [1]. Three variants circulate (CPV-2a, CPV-2b, and CPV-2c), and the Mylonakis review states they are thought to cause indistinguishable clinical disease [3]. Merck notes no association between strain and severity [1].
The virus attacks rapidly dividing cells in the intestinal crypts, lymphoid tissue, and bone marrow [1]. The resulting villous atrophy (flattening of the absorptive lining) and loss of gut barrier function allow bacteria to cross into the bloodstream. Marrow and lymphoid damage produce leukopenia, a low white cell count [1][2]. Infection in utero, or in pups under 8 weeks old or born to unvaccinated dams without naturally occurring antibodies, can cause myocarditis. Merck calls this infrequent because most bitches carry antibodies [1].
Transmission is by oronasal contact with infected feces or contaminated fomites such as equipment and personnel [1]. Merck adds that stress, intestinal parasites, and other enteric pathogens have been associated with more severe illness [1].
Clinical presentation
Per Merck, signs usually appear 5 to 7 days after infection, with a range of 2 to 14 days [1]. Early signs such as lethargy, anorexia, and fever progress within 24 to 48 hours to vomiting and hemorrhagic small bowel diarrhea, and about 25% of dogs have nonhemorrhagic diarrhea [1]. Severely affected dogs may present with signs consistent with septic shock, including prolonged capillary refill, poor pulses, tachycardia, and hypothermia [1].
Merck flags abdominal pain as a reason to rule out intussusception (telescoping of the bowel) [1]. Hypoglycemia can cause seizures, according to the Mazzaferro review [2]. That review also reports that clinical signs and examination alone reached a diagnostic accuracy of only 58% [2].
None of the cited sources describes a formal staging or classification scheme for parvoviral enteritis.
Diagnosis and testing pitfalls
Merck recommends suspecting the disease in any young or incompletely vaccinated dog with relevant signs, especially one from a shelter or breeding kennel, and confirming by fecal antigen testing or PCR [1]. Merck advises testing all dogs with relevant signs immediately so isolation can begin [1].
Sensitivity and false negatives
Reported ELISA sensitivity varies widely. The Mazzaferro review cites one study in which a common cage-side ELISA detected PCR-confirmed CPV-2a, 2b, and 2c in 80.4%, 78.0%, and 77.0% of cases [2]. The Mylonakis review puts sensitivity between 16% and 80% depending on the reference method, with specificity typically above 90% [3]. Both reviews state that sensitivity does not appear to depend on the variant [2][3].
The sources give several reasons for false negatives:
- testing before peak shedding, or after shedding falls off 10 to 12 days after infection [1]
- dilution by large-volume diarrhea [1][3]
- intestinal antibodies binding viral particles [2][3]
The Mazzaferro review states that PCR methods are "considered the most sensitive and specific" but are not immediately available in clinics. It suggests PCR when an ELISA is negative and other animals are at risk [2].
False positives after vaccination
Merck reports false positives within 4 to 10 days after modified live vaccination [1]. Both reviews add that in a recently vaccinated puppy with gastrointestinal signs, a positive test usually reflects field infection rather than vaccine virus [2][3].
Bloodwork
Most dogs develop leukopenia with lymphopenia and neutropenia. Merck lists possible biochemical findings including hypoalbuminemia, hypokalemia, hyponatremia, and hypoglycemia [1]. Merck notes that leukopenia, lymphopenia, and no band neutrophil response within 24 hours of treatment have been associated with a poor prognosis [1].
Inpatient treatment
The sources agree treatment is largely supportive [1][2][3]. Merck states that specific therapies are not available [1].
Fluids, electrolytes, and oncotic support
The Mazzaferro review describes IV fluid therapy as the "gold standard of care" and notes that jugular catheters are preferred because of contamination risk [2]. For hypovolemic dogs, it describes 20 mL/kg crystalloid boluses given while perfusion is monitored [2]. Merck states that if electrolytes and glucose cannot be monitored, empirical supplementation of potassium chloride (20 to 40 mEq/L) and dextrose (2.5% to 5%) is appropriate [1]. The Mylonakis review says potassium administration should not exceed 0.5 mEq/kg/h [3]. Merck and the Mylonakis review both describe plasma or colloids when albumin falls below 2.0 g/dL [1][3].
Antimicrobials
All three sources support antimicrobials because of bacterial translocation and neutropenia, with the Mylonakis review specifying dogs with severe disease [1][2][3]. Merck cites ampicillin sodium 22 mg/kg IV every 8 hours, with enrofloxacin or gentamicin added for severe signs or marked neutropenia [1]. The sources diverge on aminoglycosides:
- Merck says they must not be given until dehydration is corrected [1].
- The Mylonakis review says they may be considered in well-hydrated dogs [3].
- The Mazzaferro review does not recommend them because of nephrotoxicity risk [2].
Antiemetics and analgesia
Merck reports that maropitant (1 mg/kg IV or SC every 24 hours) and ondansetron (0.5 mg/kg IV every 8 hours) appear equally effective [1]. The Mazzaferro review describes a randomized prospective study in which metoclopramide, ondansetron, and maropitant were equally successful at reducing vomiting events [2].
For pain, that review notes that opioids can promote ileus and vomiting. It states that buprenorphine or butorphanol may be preferred over pure mu agonists, and calls alpha-2 agonists and NSAIDs contraindicated [2]. Merck does not recommend antidiarrheals [1].
Nutrition and adjuncts
Merck states early enteral nutrition is associated with earlier clinical improvement and better gut barrier function, and describes feeding tube placement within 12 hours of admission for anorectic dogs [1]. The sources differ on parenteral nutrition. Merck reserves it for anorexia beyond 3 days in dogs that cannot tolerate enteral feeding [1], while the Mazzaferro review calls it no longer needed [2].
Adjunct evidence is mixed:
- Merck cites one study in which fecal microbiota transplantation shortened median hospitalization to 3 days versus 6 days [1].
- Oseltamivir did not reduce hospitalization, severity, or mortality [1][3].
- Merck says feline interferon-omega has not been shown beneficial [1]. The Mylonakis review describes a 94-dog study in which it reduced severity and mortality, and notes its limited availability and high cost [3].
- The Mazzaferro review recommends antiparasite therapy once oral medication is tolerated [2].
Outpatient treatment and the monoclonal antibody
The Mazzaferro review summarizes a prospective outpatient study (sample size not stated in the review) [2]. Dogs first received IV crystalloid (15 to 45 mL/kg) until perfusion normalized, with hypoglycemia corrected using 25% dextrose at 1 to 2 mL/kg [2]. Once perfusion was restored, puppies received:
- one dose of cefovecin (8 mg/kg SC)
- maropitant (1 mg/kg SC every 24 hours)
- buprenorphine (0.02 mg/kg SC)
- a commercial diet
- oral potassium
- SC crystalloid (30 mL/kg every 6 hours) [2]
The review reports 75% to 80% survival across outpatient studies [2].
The Mylonakis review cites a study in which hospital and home survival (78.3% and 63.2%) did not differ significantly. It cautions that milder cases were likely more often treated at home [3]. Merck notes that SC fluids are insufficient for moderate to severe dehydration [1].
On the monoclonal antibody, Merck describes an experimental study in which dogs received antibody or saline when fecal shedding began, with no other therapy. No antibody-treated dogs died, against 57% of saline controls [1]. Merck did not give the sample size in its summary and states that "further studies in clinical cases will be needed" [1].
Prognosis and prevention
Prognosis
Merck gives 70% to 90% survival with appropriate supportive care, and notes that most puppies surviving the first 3 to 4 days recover fully, usually within a week [1]. The Mazzaferro review cites death in more than 90% of untreated dogs [2]. Merck states recovered dogs develop long-term, possibly lifelong, immunity [1].
Vaccination
Merck describes modified live vaccination at 6 to 8, 10 to 12, and 14 to 16 weeks, a booster 1 year later, then every 3 years [1]. The Mylonakis review reports that WSAVA-endorsed guidelines place the first booster between 6 and 12 months of age [3]. Both reviews describe shelter schedules beginning as early as 4 weeks [2][3]. The reviews note documented vaccine failures in properly vaccinated dogs [2][3].
Disinfection and isolation
Merck reports CPV can persist indoors for at least 2 months and outdoors for months or years [1]. Merck lists dilute bleach (1:30), peroxygen, potassium peroxymonosulfate, and accelerated hydrogen peroxide as effective [1]. The Mylonakis review specifies a bleach contact time of at least 10 minutes [3].
For client discussion, the sources offer specific points. Dogs shed virus for about 10 days after recovery, and Merck advises that only fully vaccinated dogs enter a home after a recent case [1].
